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Abstract
Introduction A new artificial anal sphincter,
SphinKeeperTM, was devised with the aim to treat fecal
incontinence (FI) by implanting specifically designed self-
expandable prostheses into the intersphincteric space.
Preliminary data concerning the procedure feasibility and
prosthesis localization at 3 months are presented.
Methods SphinKeeperTM prostheses in the native state are
dehydrated, thin, solid cylinder (length 29 mm, diameter
3 mm), changing their state (shorter—length 23 mm,
thicker—diameter 7 mm—and softer, with shape memory)
within 48 h of contact with fluids. In this study, 10 prostheses
were implanted in each patient with FI under local anesthesia
and under endoanal ultrasound (EAUS) guidance, into the
upper-middle intersphincteric space of the anal canal by a
specifically designed delivery system. EAUS was used
postoperatively to assess prostheses dislocation.
Results Ten patients (5 females; median age 58 years,
range 20–75) were enrolled and treated with
SphinKeeperTM implantation. Median duration of proce-
dure (performed by endoanal ultrasound guidance) was
40 min (range 30–45). Neither intraoperative nor postop-
erative complications were reported after a 3-month fol-
low-up. In one patient, a partial dislocation of a single
prosthesis was documented by EAUS, causing anal dis-
comfort which resolved after 1 week.
Conclusion SphinKeeperTM can be safely implanted in
patients with FI of different etiology. Implantation was
well tolerated with no dislodgment of implants at 3-month
follow-up.
Keywords Fecal incontinence  Artificial anal sphincter 
Sphincter lesion  Sacral nerve stimulation 
Sphincteroplasty  Bulking agents  Gatekeeper  Dynamic
graciloplasty
Introduction
Multifactorial etiology of fecal incontinence (FI) has a
significant impact on the choice of management [1–3].
Sphincter lesions are considered to be the main cause of FI,
particularly in female patients, but frequently the dys-
function occurs also in subjects with intact sphincters. In
other cases, neuropathy (either peripheral or central) plays
the pivotal role, causing sensory-motor alterations [2–7].
Also the severity of FI can be variable, ranging from
soiling, seepage and incontinence to gas (commonly
defined as ‘‘minor incontinence’’) to incontinence to liquid
and solid stools (defined as ‘‘major incontinence’’). Despite
the numerous modalities of treatment available, the thera-
peutic efficacy is still suboptimal for all of them. In fact,
‘‘conservative’’ therapies such as biofeedback have high
failure rates while the success of ‘‘minimally invasive’’
procedures such as injectable bulking agents, radiofre-
quency, tibial and sacral nerve stimulation or ‘‘aggressive’’
procedures such as anal sphincteroplasty, graciloplasty,
artificial bowel sphincter and magnetic sphincter range
from partial success to complete failure [8].
A new artificial anal sphincter, SphinKeeperTM, was
devised with the aim to surround the anal canal with
specifically designed self-expandable prostheses placed
into the intersphincteric space. Here we report the safety
data and the short term ultrasound assessment after
implantation of this device in patients with FI.
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Materials and methods
SphinKeeperTM prostheses (THD SpA, Correggio, Italy)
are made of hyexpan (polyacrylonitrile), which was pre-
viously used for the same purpose in the GatekeeperTM
(THD SpA, Correggio, Italy) [9, 10]. SphinKeeperTM
prostheses in the dehydrated state are, thin, solid cylinder
(length 29 mm, diameter 3 mm), changing their size
(shorter—length 23 mm, thicker—diameter 7 mm) and
physical properties (softer, with shape memory) within
48 h of contact with fluids (Fig. 1).
Patients were included in this study according to the
following criteria: older than 18 years and younger than
80 years, FI onset at least 6 months before the implant, a
number of FI episodes more than once a week and will-
ingness to perform baseline and follow-up schedule evalu-
ations and to sign an informed consent. Exclusion criteria
were: malignancies under treatment, rectal bleeding of
unknown origin, chronic diarrhea unresponsive to medical
treatment, inflammatory bowel disease unresponsive to
medical treatment, acute anorectal sepsis, concomitant rectal
prolapse, obstructive defecation syndrome, neurological
disease, coagulation disorder. At baseline, patients were
evaluated on the base of detailed medical history and
physical examination; when indicated, a colonoscopy was
performed. Particular attention was paid to investigate pre-
vious surgery, trauma and/or local radiotherapy, congenital
anorectal malformations, comorbidity, FI symptoms, char-
acteristic and diary, ability to defer defecation, need to wear
pads and/or taking constipating drugs, Cleveland Clinic
Fecal Incontinence Score (CCFIS), Vaizey score, AMS
score [11–13]. Health status and quality of life were evalu-
ated with SF-36 and FIQL, respectively [14, 15]. Anorectal
manometry (ARM) and endoanal ultrasound (EAUS) were
performed to assess the anorectal function and morphology.
The aim of this study was to record of intra- postoper-
ative adverse events in order to obtain data about technical
feasibility and safety. Intra- and postoperative complica-
tions were prospectively collected, in particular looking at
clinical and/or EAUS evidence of bleeding at/from the sites
of implantation, anorectal sepsis (anorectal abscess and/or
fistula), signs of local and systemic inflammation, pain,
duration of analgesics therapy and urinary retention.
Prosthesis were checked with EAUS at 1 week, 1 month
and 3 months for dislocation.
Operative procedure
Patients underwent standard bowel preparation with two
120 ml docusate sodium enemas, one the night before
and one few hours before the operation. Antibiotics
prophylaxis was given as 1 g of i.v. Cefazolin and
500 mg of i.v. Metronidazole. All implant procedures
were performed with the patient in lithotomy position,
under local anesthesia using a Mepivacaine perineal
block. Skin was prepped with povidone iodine solution.
The entire procedure was carried out under EAUS
guidance. The delivery system (Fig. 2) was loaded
before each insertion. Before insertion an activating
button was pushed for 5 s resulting in the extrusion of a
guiding cannula. Ten 2-mm perianal skin incisions were
made 2 cm from the anal margin, equidistant each other.
Under digital guidance, the introducer was inserted into
the intersphincteric space through a short subcutaneous
tunnel and pushed up to reach the upper part of the anal
canal. EAUS confirmed the correct position of the can-
nula into the intersphincteric space and the tip of the
introducer at the level of the upper third of the anal
canal. Once in place the gun was fired resulting in a
retraction of the cannula and deployment of the pros-
thesis. When the proximal part of the prosthesis reaches
the tip of the cannula, the whole cannula completely
retracts inside the delivery system and the prosthesis is
released in place in the desired position within the
intersphincteric space. The delivery device was with-
drawn. EAUS is used to confirm the position of the
prosthesis, which appears as an hyperechoic dot with a
hypoechoic shadow behind it. Three-dimensional EAUS
was used by our group and showed a continuous
hyperechoic line. The same procedure was repeated for
all 10 prostheses around the entire circumference of the
internal anal sphincter (Fig. 3). At the end of the pro-
cedure, a final 3D-EAUS imaging was carried out as final
assessment (Fig. 4). Finally, skin wounds were sutured
with resorbable material. Repeated EAUS at 1-week
documented the final dimensions of the prosthesis
(Fig. 4). All patients were strongly advised to observe
bed rest or slowly move out of bed to chair for 48 hours
to minimize early prosthesis dislocation. Lidocaine gel
and systemic painkillers (ibuprofen and tramadol) were
prescribed as needed for postoperative pain.
Fig. 1 SphinkeeperTM
prosthesis as appears in the
native, dehydrated condition
(a) and following hydration (b)
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Postoperative evaluation and follow-up
Clinical evaluation (comprehensive of FI symptoms, con-
tinence diary, FI severity scores—CCFIS, Vaizey and
AMS, FIQL and SF-36 questionnaires, physical examina-
tion and EAUS) was scheduled at 1 week, 1 month and
3 months after SphinKeeper implant. All patients were
informed about the importance of avoiding constipation
and hard stool; a diet rich in water and fibers, and oral
assumption or stool softeners were prescribed during the
first postoperative month.
Results
In the period between July 2014 and April 2015, 10 con-
secutive patients (5 men; 5 females) with a median age of
58 years (range 20–75), who met the inclusion criteria,
were enrolled in the present pilot study and treated with
SphinKeeperTM implantation. Table 1 summarizes the
baseline patients’ characteristics, including data from
clinical history, FI severity scores, previous management
of FI, health status and quality of life of the enrolled
patients.
Minimum duration of FI was 3 years, while the median
duration was 9 years. Four patients referred passive FI, 4
urge FI and 3 mixed FI. Seven patients had undergone
perineal surgical procedures, and 3 of them previous sur-
gery for FI. One patient had undergone pelvic radiotherapy
for endometrial cancer. Nine patients used pads daily.
Baseline ultrasonography and manometry data are repor-
ted, respectively, in Tables 2 and 3.
Median operative time for SphinKeeperTM implantation
under EAUS guidance was 40 min (range 30–45). Neither
intraoperative nor early postoperative complications were
reported during the hospital stay.
At 1-week EAUS evaluation, all the prostheses reached
their final size, even those implanted in scar tissue (Fig. 5).
At one week, one patient complained of anal discomfort
that, at digital examination and EAUS evaluation, was
attributed to a 1 cm distal dislocation of a single prosthesis
within the intersphincteric space, which was treated by
local and systemic painkillers (lidocaine 2 % gel and
paracetamole 1 gr tablets) until the resolution of symptoms
one week from the onset.
All patients completed the follow-up evaluation at
1 week, 1 month and 3 months. There was no postopera-
tive morbidity, in particular in terms of obstruction to the
Fig. 2 SphinkeeperTM delivery
system, showing, in detail, the
dispenser containing the
prosthesis
Fig. 3 Site of SphinkeeperTM
implantation within the
interspincteric space
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passage of stool, bleeding, anorectal sepsis, abscess or
fistula, local or systemic symptoms or chronic pain
requiring analgesics. During follow-up evaluation, no
additional case of prosthesis dislocation, extrusion or
migration was detected.
Discussion
Our study shows that SphinKeeperTM implantation is not
followed by septic or adverse reactions, does not result in
short-term dislodgement and is well tolerated. This is
promising, given the size, number, site of deployment and
elastic property of the prostheses, which are novel and
discussed below. Functional results and quality of life are
not the scope of this report given the short follow-up of
3 months.
SphinKeeperTM is the result of multiple innovations in
the treatment of FI, concerning both the device and the
implantation procedure therefore deserving the title
definition of ‘‘new artificial anal sphincter.’’ In terms of
biomechanics, SphinKeeperTM prostheses are made of a
material which has already been clinically tested [9, 10]
and has the ability to rapidly (within 2 days) self expand as
well as shape memory. Because of these characteristics, the
prostheses, even if inert have the potential to change in
shape with stool passage through the anal canal (because
soft and compressible), and regain shape and size after-
wards. This mechanism of action can be particularly useful
when the prostheses are placed into the upper and middle
anal canal, where, physiologically, the recto-anal inhibitory
reflex is elicited, starting the cascade of defecation events.
On the other hand, no obstruction developed during the
stool passage, as demonstrated in the present study.
Prostheses fit well into the anal canal. They are long
enough (23 mm in the final length) to reconstitute the
normal anal canal length and wide enough (7 mm in the
final diameter) to ensure a significant filling ability.
Moreover, the documented expansion of SphinKeeper
prostheses also within the scar tissue could give the
Fig. 4 3D-endoanal ultrasound showing the implanted SphinkeeperTM prostheses as imaged at the end of operation (a, b) and 1 week after (c, d)
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Table 1 Baseline patients’
characteristics
Patients’ characteristics Data
No. of patients 10
No. of females (%) 5 (50)
Median age (years; range) 70 (20–75)
Median age of FI onset (years; range) 53 (1–70)
Median duration of FI (years; range) 9 (3–21)
Soilinga 7 (2–49)
Gasa 14 (0–35)
Liquid stoola 3 (0–21)
Solid stoola 0 (0–7)
CCFI score 10 (5–17)
Vaizey score 13 (7–16)
AMS score 80 (26–114)
No. of patients with urinary incontinence 4
No. of patients with previous pelvic trauma 0
No. of patients with previous radiotherapy 1
No. of patients with diabetes 0
No. of patients with endocrine disease 0
No. of patients with neurological disease 0
No. of patients with gynecological disease 1
No. of patients with congenital anorectal malformation 1
No. of patients with inflammatory bowel disease (in long term remission phase) 1











Quality of life [median value (range)]
SF-36
Physical function 55 (45–90)
Role physical 25 (0–100)
Bodily pain 74 (12–90)
General health 67 (40–77)
Vitality 60 (35–75)
Social function 75 (37.5–87.5)
Role emotional 33.3 (0–100)
Mental health 68 (40–92)
FIQL score
Lifestyle 3.2 (2.1–3.8)
Coping and behavior 2.0 (1.2–2.9)
Depression and self-perception 3.6 (2.1–3.9)
Embarrassment 2.3 (2.0–4.0)
CCFI score Cleveland Clinic Fecal Incontinence Score, AMS score American Medical System Score, FI
Fecal Incontinence, SNS Sacral Nerve Stimulation
a Median number of episodes per week (range)
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opportunity to treat also patients with sphincter defects.
These aspects should be further investigated in large
number of patients.
The SphinKeeperTM procedure provides the implanta-
tion of 8–12 prostheses (always 10 in the present study).
The prosthesis is made of a material which has been
prospectively tested in the setting of fecal incontinence [9,
10], and has the advantage of being easily visualized by
ultrasound. This allows the operator to choose accurately
the implant site before the prosthesis release and, then,
activate the mechanism of delivery. The insertion and
deployment of each prosthesis takes only a few seconds.
The choice to implant the prostheses into the inter-
sphincteric space of the anal canal plays a key role. This
location potentially avoids extrusion or migration of pros-
theses (differently than if implanted into the submucosa).
Moreover, thanks to the rapid increase of their volume, the
prostheses are unlikely to move after deployment. The bed
rest which was recommended in this pilot study is aimed at
decreasing the event of an early prosthesis dislocation
(which occurred in one out of 100 prostheses implanted in
this study). As far as postoperative complications
SphinKeeperTM implant was very safe in this study; in fact,
no acute sepsis at the site of implantation and around the
prostheses was documented within 90-day period. No
Table 2 Endoanal ultrasound basal features
Features No of patients
Internal anal sphincter lesion 3
External anal sphincter lesion 4
Internal anal inhomogeneity 5
External anal inhomogeneity 5
Table 3 Anorectal manometry basal data [median (range)]
ARM parameters Features
Maximum resting pressure (mmHg) 41.5 (19.7–184.3)
Maximum squeeze pressure (mmHg) 100.9 (10.8–316.0)
Functional anal canal length (cm) 0.9 (0.8–1.3)
Threshold rectal sensation (ml) 60 (30–60)
Urge rectal sensation (ml) 100 (55–220)
Rectal maximum tolerated volume (ml) 180 (90–290)
Fig. 5 3D-endoanal ultrasound showing the implanted SphinkeeperTM prostheses in a patient with sphincter lesion, imaged at the end of
operation (a, b) and within 1 week after (c, d)
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patient had long-lasting symptoms (including anorectal pain
and discomfort) directly or indirectly related to the
implanted prostheses. This confirmed what was already
observed in a large population submitted to another type of
implantation of this material into the anal canal [9, 10].
Specifically in the case of SphinKeeperTM, a high number of
prostheses are implanted reaching a very high final volume
of implanted material (8650 mm3, approximately 480 %
increase in size of the native sphincter), surrounding the anal
canal and playing the role of an ‘‘additional’’ sphincter. The
changes in the sphincter anatomy confirmed by imaging are
expected to play a physiologic role. The hypothetical posi-
tive interaction between the SphinkeeperTM prostheses and
the adjacent IAS and EAS is interesting. Under physiolog-
ical conditions, central input (neural drive to the muscle) and
muscle length (microscopically, sarcomere length) are the
key determinants of tension and force generated by the
skeletal muscles [16]. It has been well demonstrated that
EAS muscle operates at a short sarcomere length in both
rabbits and humans; in other words, increasing its in vivo
length increases its contraction [17–21]. Our hypothesis is
that the large volume SphinkeeperTM implants, placed
between EAS and IAS (pushing the EAS outwards and the
IAS inwards), may increase the muscle fibers length and,
therefore increase their contractility. Further studies will
definitely elucidate this mechanism of action.
These properties make of SphinKeeperTM an attractive
alternative to the ‘‘external’’ artificial anal sphincters (ABS,
i.e., artificial bowel sphincter, dynamic graciloplasty, slings,
magnetic anal sphincter). In fact, in the case of ABS and
dynamic graciloplasty, only the release of the closure sys-
tem, operated by the patient, can permit the defecation,
while, in the case of anal slings and magnetic anal sphincter,
the pressure of the rectal content allows the anal canal
opening. We hypothesisze that, SphinKeeperTM, as embed-
ded into the anal canal, may improve sphincter contractility
by increasing sarcomere length as well as increase the length
of the anal canal and provide a powerful ‘‘bulking effect.’’
Following our hypothesis, in patients with loose, patu-
lous, funnel-like or keyhole-shaped anal canal,
SphinKeeperTM could offer the opportunity to reconstitute
the cylindrical shape of the anal canal, while in patients with
sphincteric lesions it could reinforce the area of scarring
improving the contribution to the continence by the
remaining intact sphincters. Finally, not insignificant could
be the role played by SphinKeeperTM as adjunctive therapy
in patients with incomplete resolution of symptoms after
other procedures for FI. In conclusion, implantation of the
SphinKeeperTM is feasible in patients with different types of
FI and does not give rise to major complications or dis-
lodgement. If proved effective it may be a viable, minimally
invasive first line approach in patients suffering from FI.
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